Cost-effectiveness of recombinant versus urinary follicle-stimulating hormone in assisted reproduction techniques in the Spanish public health care system |
| |
| Authors: | Romeu Alberto Balasch Juan Ruiz Balda José A Barri Pedro N Daya Salim Auray Jean P Duru Gerald Beresniak Ariel Peinado José A |
| |
| Affiliation: | (1) Department of Gynecology (Human Reproduction), Hospital Universitario La Fe, Valencia, Spain;(2) Institut Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clinic, Institut d'Investigacions biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;(3) Unidad de Reproducción, Hospital 12 de Octubre, Madrid, Spain;(4) Department of Obstetrics and Gynaecology, Institut Universitari Dexeus, Barcelona, Spain;(5) Department of Obstetrics & Gynecology and Clinical Epidemiology & Biostatistics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5;(6) National Center of Scientific Research (CNRS), Villeurbanne, Lyon, France;(7) Serono International S.A., Geneva, Switzerland;(8) Medical Department of Reproductive Health, Laboratorios Serono, S.A., Madrid, Spain |
| |
| Abstract: | Purpose: To evaluate the relative cost-effectiveness of recombinant and urinary follicle-stimulating hormone (FSH) in assisted reproduction techniques in the Spanish National Health Service.Methods: Markov modelling was used to compare costs and outcomes of three complete treatment cycles using recombinant or urinary FSH for controlled ovarian stimulation. Cost and effectiveness estimates were obtained from the literature and from Spanish clinicians. A Monte Carlo technique was used to randomise the distribution of outcomes at each stage. The analysis was performed by passing a virtual population of 100,000 patients through the computer simulation in each of 5000 Monte Carlo simulations.Results: The cost per pregnancy was €12,791 ± 1202 ($11,346 ± 1066) with recombinant and €13,007 ± 1319 ($11,537 ± 1170) with urinary FSH (p < 0.0001). The mean number of cycles per pregnancy was 4.69 and 5.21, respectively.Conclusions: Recombinant FSH is more cost-effective than urinary FSH in the Spanish public health care system. |
| |
| Keywords: | Cost-effectiveness Markov modelling recombinant human FSH Spain urinary FSH |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
